Jeffrey Elliott Appointed to Quanterix’s Board of Directors
19 Agosto 2024 - 3:32PM
Business Wire
Quanterix Corporation (NASDAQ: QTRX), a company fueling
scientific discovery and breakthrough diagnostics through
ultra-sensitive biomarker detection, today announced that it
appointed Jeffrey Elliott to its Board of Directors.
Mr. Elliott brings two decades of senior leadership experience
in the medical diagnostics industry, including 8 years at Exact
Sciences Corp., where he served as chief financial officer from
November 2016 to May 2024 and chief operating officer from April
2021 to May 2023. While at Exact Sciences, he was responsible for
finance, strategy and business development, helping to effectively
scale the business, achieving high revenue growth during his
tenure, and overseeing numerous acquisitions and venture
investments.
Prior to joining Exact Sciences, Mr. Elliott was a senior equity
research analyst at Robert W. Baird & Co. where he covered
health care companies, including companies in the diagnostics and
life science tools industry. He brings to Quanterix a breadth of
business strategy experience within the life sciences industry.
Mr. Elliott earned a Bachelor of Science in business
administration from the University of Illinois at Urbana-Champaign
and an M.B.A. from the University of Chicago Booth School of
Business. Mr. Elliott is a CFA® charterholder.
“We’re pleased to welcome Jeff to our board of directors at an
exciting time for the company. As Quanterix actively builds the
infrastructure for Alzheimer’s Disease testing to ensure access to
early diagnosis, Jeff's experience in scaling Exact Sciences’
operations and financial experience will be invaluable,” said
Masoud Toloue, CEO of Quanterix.
“Jeff is a wonderful addition to our Board, and we look forward
to leveraging his expertise in the industry as Quanterix continues
to grow,” said Martin Madaus, Chairman of the Board.
“It is a pivotal time in life sciences and diagnostics, and I’m
thrilled to join the Quanterix board amid great innovation and
opportunity,” said Mr. Elliott. “The mission to scale Quanterix’s
Simoa technology is bold and ambitious, and I am excited to apply
my experience to help the company achieve this goal and support
continued innovation.”
To learn more about Quanterix’s Simoa® technology, visit:
https://www.quanterix.com/simoa-technology/.
About Quanterix
From discovery to diagnostics, Quanterix’s ultra-sensitive
biomarker detection is fueling breakthroughs only made possible
through its unparalleled sensitivity and flexibility. The Company’s
Simoa® technology has delivered the gold standard for earlier
biomarker detection in blood, serum or plasma, with the ability to
quantify proteins that are far lower than the Level of
Quantification (LoQ). Its industry-leading precision instruments,
digital immunoassay technology and CLIA-certified Accelerator
laboratory have supported research that advances disease
understanding and management in neurology, oncology, immunology,
cardiology and infectious disease. Quanterix has been a trusted
partner of the scientific community for nearly two decades,
powering research published in more than 2,900 peer-reviewed
journals. Find additional information about the Billerica,
Massachusetts-based company at https://www.quanterix.com or follow
us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on
Quanterix’s expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves
risks and uncertainties. Factors that may cause Quanterix’s actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Quanterix’s filings with the U.S. Securities and Exchange
Commission, including the “Risk Factors” sections contained
therein. Except as required by law, Quanterix assumes no obligation
to update any forward-looking statements contained herein to
reflect any change in expectations, even as new information becomes
available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819478224/en/
Quanterix Media: Maya Nimnicht, PAN Communications (510)
334-6273 pan.quanterix@pancomm.com
Investor Relations: Quanterix Francis Pruell (508) 789-1725
ir@quanterix.com
Quanterix (NASDAQ:QTRX)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Quanterix (NASDAQ:QTRX)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024